Viatris (VTRS) Other Non-Current Liabilities (2019 - 2026)
Viatris (VTRS) posted Other Non-Current Liabilities of $2.0 billion for Q2 2026, down 2.85% on a QoQ basis from $2.1 billion in Q1 2026, and up 10.24% year-over-year from $1.8 billion in Q2 2025.
Analysis
Viatris (VTRS) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
Viatris has reported Other Non-Current Liabilities for 8 years, with the latest figure at $2.0 billion in Q2 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 10.24% year-over-year to $2.0 billion in Q2 2026; TTM through Jun 2026 was $2.0 billion, a 10.24% increase from a year earlier, with the FY2025 full-year figure at $2.0 billion, up 3.9% from the prior year.
- Other Non-Current Liabilities was $2.0 billion for Q2 2026 at Viatris, down from $2.1 billion in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $2.1 billion in Q1 2026, with the low at $1.5 billion in Q4 2023.
- Average Other Non-Current Liabilities over 5 years is $1.8 billion, with a median of $1.8 billion recorded in 2024.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Liabilities decreased 23.7% in 2022, then advanced 27.84% in 2024.
- Over 5 years, Other Non-Current Liabilities stood at $1.8 billion in 2022, then fell by 13.64% to $1.5 billion in 2023, then increased by 27.84% to $1.9 billion in 2024, then rose by 3.9% to $2.0 billion in 2025, then grew by 0.41% to $2.0 billion in 2026.
- The last three Other Non-Current Liabilities figures came in at $2.0 billion (Q2 2026), $2.1 billion (Q1 2026), and $2.0 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.02 Bn |
| Mar 31, 2026 | 2.08 Bn |
| Dec 31, 2025 | 2.01 Bn |
| Sep 30, 2025 | 1.82 Bn |
| Jun 30, 2025 | 1.84 Bn |
| Mar 31, 2025 | 1.84 Bn |
| Dec 31, 2024 | 1.94 Bn |
| Sep 30, 2024 | 1.87 Bn |
| Jun 30, 2024 | 1.80 Bn |
| Mar 31, 2024 | 1.83 Bn |
| Dec 31, 2023 | 1.52 Bn |
| Sep 30, 2023 | 1.65 Bn |
| Jun 30, 2023 | 1.67 Bn |
| Mar 31, 2023 | 1.72 Bn |
| Dec 31, 2022 | 1.76 Bn |
| Sep 30, 2022 | 1.75 Bn |
| Jun 30, 2022 | 1.81 Bn |
| Mar 31, 2022 | 1.88 Bn |
| Dec 31, 2021 | 1.93 Bn |
| Sep 30, 2021 | 2.05 Bn |